A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study
Margherita Fabbri, Clémence Leung, Guillaume Baille, Matthieu Béreau, Christine Brefel Courbon, Giovanni Castelnovo, Nicolas Carrière, Philippe Damier, Luc Defebvre, Anne Doé de Maindreville, Frédérique Fluchère, Marie Fuzzatti, David Grabli, David Maltête, Vanessa Rousseau, Agnès Sommet A, Claire Thalamas, Claire Thiriez, Olivier Rascol, Fabienne Ory‐Magne
Topics & Concepts
MedicinePandemicWeaknessParkinson's diseaseCoronavirus disease 2019 (COVID-19)DiseasePhysical therapyQuality of life (healthcare)Motor symptomsFamily medicineInfectious disease (medical specialty)Internal medicineNursingAnatomyParkinson's Disease Mechanisms and TreatmentsParkinson's Disease and Spinal DisordersLong-Term Effects of COVID-19